// App-Quantinova.ai

PR‐001 : Pml nuclear body disruption cooperates in APL pathogenesis, impacting DNA damage repair pathways

Researchers

Presenter

  • E Voisset

Principal Investigators

  • E Moravcsik

  • E Stratford

  • A Jaye

  • C Palgrave

  • R Hills

  • P Salomoni

  • S Kogan

  • E Solomon

  • D Grimwade

Medical Centers

  • Medical and Molecular Genetics, Kings College, London, London, United Kingdom

  • Tumor Biology,The Norwegian Radium Hospital,Oslo,Norway

  • Kings College London, London, UK

  • University of Surrey, Guildford, Surrey, UK

  • Centre for Trials Research, College of Biomedical & Life Sciences, Cardiff

  • Samantha Dickson Brain Cancer Unit, UCL Cancer Institute, London, United Kingdom

  • Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA

Locations

  • United Kingdom

  • Norway

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Promyelocytic Leukemia

  • Tumor suppressor p53-binding protein 1

Drug/Treatment

  • Cysteine Hydrochloride

  • Tretinoin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved